PMID: 9632381Jun 25, 1998Paper

The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens

Science
R Wyatt, J Sodroski

Abstract

The human immunodeficiency virus-type 1 (HIV-1) envelope glycoproteins interact with receptors on the target cell and mediate virus entry by fusing the viral and cell membranes. The structure of the envelope glycoproteins has evolved to fulfill these functions while evading the neutralizing antibody response. An understanding of the viral strategies for immune evasion should guide attempts to improve the immunogenicity of the HIV-1 envelope glycoproteins and, ultimately, aid in HIV-1 vaccine development.

References

Jun 1, 1992·AIDS Research and Human Retroviruses·S KarwowskaS Zolla-Pazner
Dec 14, 1989·The New England Journal of Medicine·D D HoM Alam
Nov 1, 1995·Journal of Virology·J T LiJ G Sodroski
Jul 1, 1995·The Journal of Experimental Medicine·Q J Sattentau, J P Moore
Jun 1, 1994·AIDS Research and Human Retroviruses·T J Matthews
Sep 15, 1993·Biochemical and Biophysical Research Communications·S JiangA R Neurath
May 22, 1997·Nature·W WeissenhornD C Wiley
Dec 31, 1997·Science·K A MartinN P Gerard

❮ Previous
Next ❯

Citations

Mar 14, 2000·Reviews in Medical Virology·M Flint, J A McKeating
Apr 7, 2010·Archivum Immunologiae Et Therapiae Experimentalis·Milan Raska, Jan Novak
May 27, 2008·Cellular and Molecular Life Sciences : CMLS·H Garg, R Blumenthal
Jul 31, 2013·Planta·Dania O Govea-AlonsoSergio Rosales-Mendoza
Aug 5, 2011·Archives of Virology·Salvatore DimonteMuhammed Babakir-Mina
Dec 17, 2009·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Vanessa Rivera-AmillAnil Kumar
Aug 11, 2005·Current HIV/AIDS Reports·M Patricia D'SouzaMargaret I Johnston
Mar 9, 2006·Current HIV/AIDS Reports·Isaac R Rodriguez-ChavezM Patricia D'Souza
Jul 16, 2013·Trends in Microbiology·Lesley A EarlSriram Subramaniam
Apr 3, 2004·Trends in Pharmacological Sciences·Shawn E Kuhmann, John P Moore
Jun 15, 2004·Vaccine·Thomas G EvansUNKNOWN HIV Vaccine Trials Network (HVTN 803)
Sep 25, 2002·Biochemical and Biophysical Research Communications·Hong LingToshio Hattori
Apr 15, 1999·Immunology Letters·Q J SattentauS Ugolini
May 23, 2001·Antiviral Research·C C LaBrancheS M Hammer
Jun 22, 2002·Antiviral Research·Vladimir RazinkovGirija Krishnamurthy
Apr 11, 2003·Virus Research·Gary J Nabel
Oct 11, 2003·Biotechnology Advances·J W Semple
Jan 6, 2001·Infectious Disease Clinics of North America·R Dolin
Apr 28, 1999·Trends in Microbiology·S UgoliniQ J Sattentau
Apr 28, 2001·Cytokine & Growth Factor Reviews·T S Stantchev, C C Broder
May 2, 2000·Drug Discovery Today·W S BlairO B Wallace
Oct 6, 2001·Current Opinion in Microbiology·M D Miller, D J Hazuda
Feb 26, 2003·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Louise A Cooley, Sharon R Lewin
Sep 27, 2002·Current Opinion in Pharmacology·Mark J BisconeRobert W Doms
Apr 15, 2011·Expert Reviews in Molecular Medicine·Viet Loan Dao ThiFrançois-Loïc Cosset
Sep 7, 2006·Biochemistry·Arne SchönErnesto Freire
Apr 15, 2011·Biochemistry·Indira Shrivastava, Judith M LaLonde

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antigenic Modulation

Antigenic modulation occurs when an antibody cross-links antigens on a cell surface, causing the antigens to become internalized. This can lead to therapeutic failure of monoclonal antibodies as the expression of the antigen becomes decreased on target cells. Find the latest research on antigenic modulation here.